Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: a 24‐week real‐life experience

Patients with urothelial cell carcinoma (UCC) often have comorbidities, which cause trouble for the completion of oncological treatment, and little is known about their quality of life (QoL). The aim of the present study was to obtain and describe patient-reported outcomes (PRO) and QoL data from UCC patients in the treatment for locally advanced muscle-invasive or metastatic UCC. A total of 79 patients with UCC completed four questionnaires (EORTC QLQ-C30, QLQ-BLM30, HADS, and select PRO-CTCAE™ questions) once weekly during their treatment. From those, 26 patients (33%) underwent neoadjuvant treatment for local disease while 53 patients (67%) were treated for metastatic disease. Of all patients, 54% did not complete the planned treatment due to progression, nephrotoxicity, death, or intolerable symptoms during treatment. The five most prevalent PRO-CTCAE grade ≥ 2 symptoms were frequent urination (37%), fatigue (35%), pain (31%), dry mouth (23%), and swelling of the arms or legs (23%). The baseline mean overall QoL was 61 (±SD 24) for all patients (neoadjuvant (73, ±SD 19) and metastatic (54, ±SD 24)) and remained stable over the course of treatment for both groups. A stable overall QoL was observed for the patients in this study. More than half of the patients did not, however, complete the planned treatment. Further supportive care is warranted for bladder cancer patients.

Download Full-text

A New Curcuma Extract (Flexofytol®) in Osteoarthritis: Results from a Belgian Real-Life Experience

The Open Rheumatology Journal ◽

10.2174/1874312901408010077 ◽

2014 ◽

Vol 8 (1) ◽

pp. 77-81 ◽

Cited By ~ 22

Author(s):

Thierry Appelboom ◽

Nathalie Maes ◽

Adelin Albert

Keyword(s):

Quality Of Life ◽

Patient Satisfaction ◽

Observational Study ◽

Life Experience ◽

Real Life ◽

Randomized Controlled ◽

Randomized Controlled Studies ◽

Patient Pain ◽

Inflammatory Drugs

This retrospective observational study summarizes the experiences of 820 patients treated with a new Curcuma extract (Flexofytol®, 4-6 capsules per day), for more than 6 months for various forms of painful osteoarthritis. These experiences were reported by 110 Belgian general practitioners via a questionnaire that included quality-of-life parameters for assessing patient experience. Data were submitted to an independent statistician for analysis. Within the first 6 weeks, Flexofytol® improved patient pain, articular mobility, and quality of life. Excellent tolerance was reported, and more than half of these patients were able to discontinue analgaesic and anti-inflammatory drugs. Patient satisfaction was confirmed by their decision to maintain Flexofytol® therapy for more than 6 months. These data must be confirmed with randomized controlled studies. We currently conclude that Flexofytol® which is based on a new preparation of curcumin, is as a potential neutraceutical for the care of patients complaining of joint problems, with excellent tolerance and rapid benefits for articular mobility, pain, and quality of life.

Download Full-text

Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation

Patient Preference and Adherence ◽

10.2147/ppa.s131158 ◽

2018 ◽

Vol Volume 12 ◽

pp. 79-87 ◽

Cited By ~ 26

Author(s):

Michaël Benzimra ◽

Béatrix Bonnamour ◽

Martin Duracinsky ◽

Christophe Lalanne ◽

Jean-Pierre Aubert ◽

...

Keyword(s):

Quality Of Life ◽

Atrial Fibrillation ◽

Treatment Satisfaction ◽

Life Experience ◽

Oral Anticoagulants ◽

Real Life

Download Full-text

Real-life experience of efficacy and safety of bilastine in the refractory cases of chronic spontaneous urticaria and its effect on the quality of life of patients

Indian Journal of Dermatology ◽

10.4103/ijd.ijd_771_20 ◽

2021 ◽

Vol 66 (2) ◽

pp. 159

Author(s):

Abhishek De ◽

Kiran Godse ◽

Dhiraj Dhoot ◽

Aarti Sarda

Keyword(s):

Quality Of Life ◽

Life Experience ◽

Real Life ◽

Chronic Spontaneous Urticaria ◽

Efficacy And Safety

Download Full-text

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience

Frontiers in Pharmacology ◽

10.3389/fphar.2021.631660 ◽

2021 ◽

Vol 12 ◽

Author(s):

Giulia Scioscia ◽

Giovanna Elisiana Carpagnano ◽

Carla Maria Irene Quarato ◽

Donato Lacedonia ◽

Sonia Santamaria ◽

...

Keyword(s):

Quality Of Life ◽

Lung Function ◽

Asthma Control ◽

Severe Asthma ◽

Life Experience ◽

Real Life ◽

Eosinophilic Inflammation ◽

Eosinophilic Asthma ◽

Severe Eosinophilic Asthma

Background: Severe eosinophilic asthma decreases lung function and causes worsen symptoms, often forcing recurrent maintenance corticosteroid use. The aim of our real-life study was to evaluate the effectiveness of an add-on treatment with benralizumab in patients with severe eosinophilic asthma, paying particular attention to the impact on their quality of life (QoL).Materials and methods: In this prospective study, 10 outpatients with severe eosinophilic asthma were added-on with benralizumab and followed-up in our severe asthma clinic after 12 and 24 weeks. At each patient visit, pre-bronchodilator FEV1 and inflammatory markers were recorded. Variations in asthma symptoms control and QoL perception was assessed by validated questionnaires.Results: All the subjects experienced a marked reduction of nocturnal and diurnal symptoms over time and were able to stop using OCS, as documented by the improvement in Asthma control test (ACT) and Asthma Control Questionnaire score. Similarly, we recorded a statistically significant increase in patient’s QoL perception in EQ-VAS, EQ-5D-3L and Asthma Quality of Life Questionnaire (AQLQ) assessment (p < 0.05). Simultaneously we recorded a significant reduction in eosinophilic inflammation, an improvement in pre-bronchodilator FEV1. These results appear to be in line with those already obtained in the previous randomized controlled trials (RCTs).Conclusion: Our 24-weeks real life experience supports the effectiveness of an add-on treatment with benralizumab in reducing eosinophilic inflammation and OCS-use, increasing lung function and improving control of nocturnal and diurnal symptoms, as well as restoring severe asthma patients to a better QoL.

Download Full-text